RGNX Regenxbio (RGNX) Insider Trading, Ownership & Congress Trades
Pharma & Biotech · Biological products, (no diagnostic substances) · CIK 0001590877
SEC filings
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
85
13F, latest reported quarter
Conversions, 180 days
2
Codes C/M, not in net · $305.6K priced
What the filings say about RGNX
Insiders, 180 days
+$62.4K net bought
1 buyer · 1 seller · 0% of sales under a 10b5-1 plan
Regenxbio insider trades (Form 4)
Form 4 buys and sells (codes P and S). Grants, option exercises
and conversions excluded.
Over the last 180 days, REGENXBIO Inc. insiders bought a net $62.4K of stock across 50 Form 4 purchases and sales, with 1 insider buying. Source: SEC Form 4 filings, as of 2026-10-28.
Insider
Filed
Shares
Value
Since filing
Context
- 1 earlier Form 4 trade (code P or S) here by this insider (1 buy), the last on Aug 26, 2026.
- The trade is 45.2% of the 118,035 shares held after it.
- No other insider bought within 30 days.
- 85 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Ciongoli Gregory Austin bought about $499.7K of RGNX on Aug 27, 2026, the largest insider purchase at the company on our record; 85 funds added in the latest 13F quarter.Context
- First Form 4 purchase or sale (code P or S) here by this insider on our record.
- The trade is 76.1% of the 64,628 shares held after it.
- No other insider bought within 30 days.
- 85 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Ciongoli Gregory Austin bought about $449.7K of RGNX on Aug 26, 2026, the largest insider purchase at the company on our record; 85 funds added in the latest 13F quarter.Context
- 8 earlier Form 4 trades (code P or S) here by this insider (8 sales), the last on Jul 1, 2026.
- The trade is 1.0% of the 213,009 shares held after it.
- No other insider sold within 30 days.
- 85 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Medical Officer PAKOLA STEVE sold about $29.5K of RGNX on Jul 2, 2026; 85 funds added in the latest 13F quarter.Context
- 7 earlier Form 4 trades (code P or S) here by this insider (7 sales), the last on Jun 29, 2026.
- The trade is 17.2% of the 213,009 shares held after it.
- No other insider sold within 30 days.
- 85 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Medical Officer PAKOLA STEVE sold about $472.3K of RGNX on Jul 1, 2026, the largest insider sale at the company since 2024; 85 funds added in the latest 13F quarter.Context
- 6 earlier Form 4 trades (code P or S) here by this insider (6 sales), the last on May 11, 2026.
- The trade is 9.2% of the 213,009 shares held after it.
- No other insider sold within 30 days.
- 85 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Medical Officer PAKOLA STEVE sold about $216.5K of RGNX on Jun 29, 2026; 85 funds added in the latest 13F quarter.50 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
Seven facts, ranked against the sector ·
Rank is not a forecast
Insiders
net +$62.4K over 180 days
+$949.4K over 90 days
more than 74% of Pharma & Biotech
Congress
no House purchase disclosed in the last 12 months
Funds
85 funds bought in last quarter
more than 62% of Pharma & Biotech
Revenue
+104.5% year over year
more than 84% of Pharma & Biotech
Margin
-113.8% net margin
below 59% of Pharma & Biotech
Buybacks
no share repurchases reported
Short interest
16.8% of the float short (float per yahoo 2026-10-26) · 6.0 days to cover · settled 2026-09-30
more than 84% of Pharma & Biotech
What changed in the last 30 days
Oct 28Insider selling stopped: no sales in 90 days after 4 in the prior 90
Why it matters
The absence is the signal: 4 sales in one 90-day window and none in the next is a change of behaviour, not a filing.
Watch RGNX
A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.
The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
-47.7%12M
Insider buyInsider sellForm 144 (planned sale)
Indexed to 100, dividend-adjusted, not a price chart.
When a name files heavily, the largest trades are drawn first.
Who owns RGNX: institutional holders (13F)
13F holdings, latest reported quarter
6,397,440 sh
$76.6M
4,368,804 sh
$52.3M
2,971,173 sh
$35.6M
2,214,169 sh
$26.2M
2,107,557 sh
$25.2M
Congress trades in RGNX
No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.
Activist and 5% holders (13D/13G)
No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.
RGNX planned insider sales (Form 144)
Notice of intent to sell, filed before any sale
Stephen J. Pakola
Filed 2026-07-01
$517.6K
RGNX mutual fund holders (N-PORT)
Funds ranked by the share of their own portfolio in this stock (N-PORT).
Virtus Biotech Clinical Trials Etf
$452.2K position · as of 2026-07-31
1.0%
VANGUARD MARKET NEUTRAL FUND
$3.4M position · as of 2026-06-30
0.6%
Global X Genomics & Biotechnology ETF
$181.5K position · as of 2026-05-31
0.3%
JPMorgan Small Cap Growth Fund
$7.5M position · as of 2026-06-30
0.3%
MFS Blended Research Small Cap Equity Portfolio
$218.1K position · as of 2026-06-30
0.3%
Nomura Healthcare Fund
$1.8M position · as of 2026-06-30
0.2%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M ·
% is the share of the fund's own portfolio
Clinical pipeline
13 registered trials, 7 still running (ClinicalTrials.gov).
A status change is dated here weeks before the press release.
1
Phase 3
1 active
6
Not applicable
4 active
6
Multi-phase
2 active
Matched by sponsor name. Trials run under a subsidiary's
own name are not included.
Executive pay vs shareholder return · Kenneth TMills
CEO pay, headline and as actually paid, against the company's
return and its chosen peers' (DEF 14A).
FY
CEO total
Actually paid
Other execs, avg
TSR
Peer TSR
2023
$5.9M
$3.0M
$3.0M
-21%
n/a
Tagged by the company under SEC Item 402(v). Returns are
cumulative from the start of the disclosure period. Green where the company beat its own peer group.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
Insiders are net buyers of their own stock.
The record shows a net $62.4K bought by insiders over 180 days, 85 funds added last quarter. Each figure is a federal filing, dated the day it went public.
RGNX financials
Revenue growth
+104.5%
XBRL, annual
Net margin
-113.8%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$174.5M
four quarters, 2025-07-01 to 2026-06-30
Revenue, TTM RGNX
| FY Dec 2025 | $170.4M |
| FY Dec 2024 | $83.3M |
| FY Dec 2023 | $90.2M |
| FY Dec 2022 | $112.7M |
| FY Dec 2021 | $470.3M |
| Jun 2026 | $108.0M |
| Mar 2026 | $6.4M |
| Dec 2025 | $30.3M |
| Sep 2025 | $29.7M |
| Jun 2025 | $21.4M |
| Mar 2025 | $89.0M |
| Dec 2024 | $21.2M |
| Sep 2024 | $24.2M |
At each fiscal year end
Single quarter
Net margin, TTM
-112.6%
net income over revenue, 2025-07-01 to 2026-06-30
Net margin, TTM RGNX
| FY Dec 2025 | -113.8% |
| FY Dec 2024 | -272.5% |
| FY Dec 2023 | -292.0% |
| FY Dec 2022 | -248.7% |
| FY Dec 2021 | +27.2% |
| Jun 2026 | +21.0% |
| Mar 2026 | -1,409% |
| Dec 2025 | -221.3% |
| Sep 2025 | -208.3% |
| Jun 2025 | -331.8% |
| Mar 2025 | +6.8% |
| Dec 2024 | -241.3% |
| Sep 2024 | -246.3% |
At each fiscal year end
Single quarter
Free cash flow, TTM
-$249.7M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Free cash flow, TTM RGNX
| FY Dec 2025 | -$126.4M |
| FY Dec 2024 | -$175.6M |
| FY Dec 2023 | -$228.4M |
| FY Dec 2022 | -$238.2M |
| FY Dec 2021 | $134.7M |
| Jun 2026 | -$63.0M |
| Mar 2026 | -$77.4M |
| Dec 2025 | -$52.8M |
| Sep 2025 | -$56.5M |
| Jun 2025 | -$49.7M |
| Mar 2025 | $32.6M |
| Dec 2024 | -$32.7M |
| Sep 2024 | -$40.9M |
At each fiscal year end
Single quarter
Debt to equity
n/a
no debt line filed
Debt to equity RGNX
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Cash flow to debt
n/a
no debt line filed
Cash flow to debt RGNX
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Return on equity
-137.6%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on equity RGNX
| FY Dec 2025 | -107.0% |
| FY Dec 2024 | -79.5% |
| FY Dec 2023 | -63.7% |
| FY Dec 2022 | -43.8% |
| FY Dec 2021 | +22.4% |
| Jun 2026 | -137.6% |
| Mar 2026 | -196.4% |
| Dec 2025 | -107.0% |
| Sep 2025 | -76.9% |
| Jun 2025 | -62.5% |
| Mar 2025 | -47.4% |
| Dec 2024 | -79.5% |
| Sep 2024 | -71.9% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on assets
-40.6%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets RGNX
| FY Dec 2025 | -42.2% |
| FY Dec 2024 | -43.7% |
| FY Dec 2023 | -37.4% |
| FY Dec 2022 | -28.8% |
| FY Dec 2021 | +14.0% |
| Jun 2026 | -40.6% |
| Mar 2026 | -69.6% |
| Dec 2025 | -42.2% |
| Sep 2025 | -34.1% |
| Jun 2025 | -30.5% |
| Mar 2025 | -28.2% |
| Dec 2024 | -43.7% |
| Sep 2024 | -41.4% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on invested capital
n/a
pre-tax loss, no effective tax rate to apply
Return on invested capital RGNX
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Return on capital employed
-42.9%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
Return on capital employed RGNX
| FY Dec 2025 | -46.2% |
| FY Dec 2024 | -57.9% |
| FY Dec 2023 | -46.8% |
| FY Dec 2022 | -31.2% |
| FY Dec 2021 | +19.9% |
| Jun 2026 | -42.9% |
| Mar 2026 | -78.4% |
| Dec 2025 | -46.2% |
| Sep 2025 | -37.9% |
| Jun 2025 | -35.3% |
| Mar 2025 | -34.8% |
| Dec 2024 | -57.9% |
| Sep 2024 | -53.3% |
At each fiscal year end
Trailing four quarters at each quarter end
P/E, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
P/E, trailing RGNX
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Enterprise value
n/a
no debt line filed
Enterprise value RGNX
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
FCF yield
-57.5%
TTM free cash flow over market value at close 2026-10-26
FCF yield RGNX
| FY Dec 2025 | -17.3% |
| FY Dec 2024 | -45.8% |
| FY Dec 2023 | -28.9% |
| FY Dec 2022 | -24.3% |
| FY Dec 2021 | +9.6% |
| Jun 2026 | -40.3% |
| Mar 2026 | -54.7% |
| Dec 2025 | -17.3% |
| Sep 2025 | -21.8% |
| Jun 2025 | -22.0% |
| Mar 2025 | -24.3% |
| Dec 2024 | -45.8% |
| Sep 2024 | -35.6% |
At each fiscal year end
Trailing four quarters at each quarter end
PEG, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
PEG, trailing RGNX
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Price as of 2026-10-26. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
| 2025-12 | 2024-12 | 2023-12 | 2022-12 | |
|---|---|---|---|---|
| Revenue | $170.4M | $83.3M | $90.2M | $112.7M |
| Operating income | -$161.2M | -$233.3M | -$268.1M | -$262.9M |
| Net income | -$193.9M | -$227.1M | -$263.5M | -$280.3M |
| EPS (diluted) | -3.76 | -4.59 | -6.02 | -6.50 |
| Operating cash flow | -$124.0M | -$173.1M | -$218.4M | -$207.5M |
| Cash | $34.5M | $57.5M | $34.5M | $97.0M |
SEC XBRL, fiscal years, as known on 2026-10-28
RGNX Stock Sonar score 5/7 axes
Find similar shapesCompareRGNX ranks highest on growth (84th percentile) and insider conviction (65th), and lowest on risk and compliance (30th), among Pharma & Biotech peers.
5 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored
RGNX filings, in plain words
Are Regenxbio insiders buying or selling RGNX?
In the 180 days to 2026-10-28, Regenxbio insiders were net buyers, a net $62.4K: $949.4K of purchases and $886.9K of sales reported on Form 4, by 1 buyer and 1 seller.
Read the full summary
In the 180 days to 2026-10-28, Regenxbio insiders were net buyers of RGNX, a net $62.4K across purchases and sales reported on Form 4 by 1 buyer and 1 seller. None of the 4 insider sales was flagged as made under a Rule 10b5-1 plan. Each figure is counted from SEC and House filings as of 2026-10-28, dated the day the filing was made public.
Explore insider trading and ownership data
Every company we track, ranked by each kind of filing
